Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia

Haematologica

Volumn 92, Issue 2, 2007, Pages

  Ma, Wanlong ^a   Tseng, Richard ^a   Gorre, Mercedes ^a   Jilani, Iman ^a   Keating, Michael ^b   Kantarjian, Hagop ^b   Cortes, Jorge ^b   O'Brien, Susan ^b   Giles, Francis ^b   Albitar, Maher ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BCR ABL; Chronic myeloid leukemia; Imatinib; Plasma; RT PCR

Indexed keywords

BCR ABL PROTEIN; IMATINIB; NUCLEIC ACID; RNA; ANTINEOPLASTIC AGENT; MESSENGER RNA; PIPERAZINE DERIVATIVE; PRIMER DNA; PYRIMIDINE DERIVATIVE;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; BLOOD; CASE CONTROL STUDY; CELL STRAIN K 562; CHEMISTRY; GENETICS; METABOLISM; METHODOLOGY; MONITORING; REPRODUCIBILITY;

ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; DNA PRIMERS; FUSION PROTEINS, BCR-ABL; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, CHRONIC; MONITORING, PHYSIOLOGIC; PIPERAZINES; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; RNA, NEOPLASM;

EID: 33947519183     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10360     Document Type: Article

References (15)

1. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Scniffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346:645-52.
2. Muller MC, Gattermann N, Lahaye T, Deininger MW, Bemdt A, Fruehauf S, et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C. Leukemia 2003; 17:2392-400.
3. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. The IRIS Investigators. N Engl J Med 2003; 348:994-1004.
4. Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005;11:3425-32.
5. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. International Randomised Study of Interferon versus STI571 (IRIS) Study Group. N Engl J Med 2003;349:1423-32.
6. Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α. Blood 2004; 104: 1979-88.
7. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873-8.
8. Press RD, Love Z, Tronnes AA, Yang R, Tran T, Mongoue-Tchokote S, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib-treated patients with CML. Blood 2006; 107: 4250-6.
9. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006;103:2794-9.
10. Kantarjian HM, Talpaz M, Cortes J, O'Brien S, Faderl S, Thomas D, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 2003;9:160-6.
11. Ahmed M, Giles F, Joe Y, Weber DM, Jilani I, Manshouri T, et al. Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma. Eur J Haematol 2003; 71:174-8.
12. Albitar M, Do KA, Johnson MM, Giles FJ, Jilani I, O'Brien S, et al. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer 2004;101:999-1008.
13. Jilani I, Keating M, Giles FJ, O'Brien S, Kantarjian HM, Albitar M. Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay. Leuk Res 2004;28: 1255-62.
14. Manshouri T, Do KA, Wang X, Giles FJ, O'Brien SM, Saffer H, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003; 101: 2507-13.
15. Rogers A, Joe Y, Manshouri T, Dey A, Jilani I, Giles F, et al. Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia. Blood 2004;103:2799-801.